INOTREM
Budget
€10 — €0
EP Access
0
accredited persons
Staff
1
0.1 FTE
EU Grants
None
Mission & Goals
Inotrem is a late-stage clinical biotechnology company based in France. Its mission is to improve public health by developing a new class of therapeutics targeting the immunological pathway TREM-1 with a personalized medicine approach to manage acute, life-threatening immune dysregulations with high unmet medical need. Given TREM-1’s role in amplifying immune responses across infectious diseases, Inotrem’s lead candidate nangibotide - a peptidic inhibitor of TREM-1 - represents a potential medical countermeasure for acute inflammatory syndromes caused by emerging pathogens with pandemic potential. Nangibotide has shown clinical efficacy in two Phase 2b trials, in septic shock and in severe COVID-19, demonstrating the potential of nangibotide as a pathogen-agnostic countermeasure and paving the way for the first precision medicine in acute care. Inotrem aims to bring nangibotide to market authorisation in a broad range of acute indications, with septic shock as its lead indication.
EU Legislative Interests
Inotrem is mostly interested in the following EU legislation and policies: the Health Emergency and Preparedness Response Authority (HERA) Medical CounterMeasures strategy, the Critical Medicines Act, the EU Biotech Act, the EU Innovation Act, the EU Start-Up and Scale-Up Strategy. Primarily, Inotrem is applying for membership to the Joint Industrial Cooperation Forum as a sub-group of HERA Advisory Forum, in order to contribute to public-private collaborations towards funding and developing solutions that enhance the availability and security of supply of medical countermeasures by mature biotech companies, in line with the Preparedness Union Strategy.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Inotrem is representing European biotechnology SMEs performing pharmaceutical research and development activities. Besides, Inotrem has been keen on interacting with two key groups of experts and advocates in the fight against sepsis: - The International Sepsis Forum (ISF, www.sepsisforum.org) is a group of global experts in the epidemiology, pathogenesis, management, outcomes, and prevention of sepsis; we have regularly attended the ISF annual congress as an opportunity to exchange with key experts in the field; - The Global Sepsis Alliance (GSA, www. globalsepsisalliance.org) is a non-profit charity organisation with the mission to provide global leadership to reduce the worldwide burden of sepsis. Inotrem has actively engaged with the GSA and its regional European branch, the European Sepsis Alliance, notably by attending their annual meetings in Brussels. We have endorsed the 2030 World Sepsis Declaration, sharing the key objectives of the 2030 Global Agenda on Sepsis. Inotrem maintains regular contact with the GSA to exchange updates and explore opportunities to support and sponsor its awareness and advocacy initiatives.
Additional Information
Inotrem is aiming to increase its Public Affairs activities, notably through the application of its COO as member to HERA’s Joint Industrial Cooperation Forum.
Commissioner Meetings
No recorded meetings with EU commissioners.